Abbott and Google Health join forces to bring AI-powered glucose insights to everyday users

More than 115 million American adults are living with prediabetes. And roughly eight in ten of them have no idea. That single statistic is at the heart of a new partnership between Abbott and Google Health, announced on August 11, 2026, and it points to a much larger problem: most people do not act on health risks they cannot see.

The collaboration pairs Abbott's Lingo biowearable, an over-the-counter continuous glucose monitor (CGM) designed for non-diabetic adults, with Google Health's artificial intelligence capabilities. The aim is to give users a clearer, more connected picture of how their daily habits affect their metabolic health, before problems become diagnoses.

Lingo is not a clinical device. It is designed for adults aged 18 and over who are not using insulin and want to understand how their body responds to food, movement, sleep, and stress. Until now, that data lived in its own silo. This partnership changes that.

How will it work?

Through an integration with the Google Health app, Lingo users will be able to view their glucose trends alongside other health metrics in a single interface. The idea is that context makes the data useful. Seeing that your glucose spiked after a poor night's sleep, or dropped during a walk, gives the numbers meaning they do not have in isolation.

Google Health Coach, which requires a Google Health Premium subscription, will then use those insights to deliver personalised recommendations across four areas:

• Nutrition choices and meal timing
• Physical activity and movement patterns
• Sleep quality and recovery
• Stress management behaviours

The partnership also includes a large-scale real-world research study, described by Abbott as one of the biggest of its kind, looking at the relationship between glucose patterns and everyday behaviours. The findings are intended to inform future AI-driven health guidance.

Why does it matter?

Metabolic health is increasingly recognised as a leading indicator of long-term chronic disease risk. Poor glucose regulation is linked not just to Type 2 diabetes, but to cardiovascular disease and certain cancers. The challenge has always been that the people most at risk are often the least aware of it.

Wearable CGM technology has existed in clinical settings for years. But making it accessible and, more importantly, interpretable for healthy adults is a different problem. Data without guidance tends to produce anxiety, not behaviour change. The Google Health Coach integration is designed to close that gap, turning glucose readings into specific, contextual suggestions rather than raw numbers.

For the GCC region, this development carries particular relevance. The Gulf states face some of the highest rates of diabetes and prediabetes in the world. Saudi Arabia's Vision 2030 health targets and the UAE's various national health strategies all identify non-communicable disease prevention as a priority. Tools that shift the emphasis from treatment to early lifestyle intervention align directly with those goals. As consumer CGM technology matures and AI health coaching becomes more sophisticated, regional health authorities and insurers will be watching closely to see whether this kind of product can demonstrate measurable outcomes at scale.

The context

Abbott has been building its consumer glucose monitoring business steadily since the success of its clinical FreeStyle Libre platform. Lingo represents a deliberate push into the wellness market, positioning CGM not as a medical device but as a health insight tool. Google Health, meanwhile, has made several attempts over the years to become a meaningful player in consumer health. This partnership gives it a hardware-linked data stream it has not had before.

Lingo is currently available in the United States and the United Kingdom. Google Health integrations are expected to roll out later in 2026. For those interested in following the product's development, Abbott has directed users to hellolingo.com for updates.

The broader question, one that policymakers and clinicians in the Arab world should be tracking, is whether AI-assisted metabolic monitoring can genuinely shift health behaviours at a population level. The research component of this partnership may eventually offer some answers. But the commercial bet being placed here is clear: that the future of preventive health is personal, continuous, and powered by data people actually want to look at.